研究单位：[1]CARsgen Therapeutics Co., Ltd.[2]Shanghai Zhongshan Hospital[3]Fudan University[4]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[5]Hunan Provincial People's Hospital,Changsha,China[6]Sichuan Cancer Hospital,Chengdu,China[7]West China Hospital of Sichuan University,Chengdu,China[8]Chongqing university ca cer hospital,Chongqing,China[9]Mengchao hepatobiliary hospital of fujian medical university,Fuzhou,China[10]Sun Yat-sen University Cancer Center,Guanzhou,China[11]Sir Run Run Shaw Hospital Zhejiang University School of Medicine,Hangzhou,China[12]The second affiliated hospital zhejiang university school of medicine,Hangzhou,China[13]Zhongshan Hospital Fudan University,Shanghai,China[14]Liaoning Cancer Hospital,Shenyang,China[15]The first hospital of china medical university,Shenyang,China[16]Tianjin medical university cancer hospital,Tianjin,China[17]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology,Wuhan,China[18]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China
A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.
